Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib

A number of CML patients who achieve a sustained complete molecular response (CMR) for at least 2 years during imatinib (IM) therapy can discontinue IM without relapse. With the long‐term goal of developing immunological criteria for managing IM therapy in CML patients, we compared the immunophenoty...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Mizuguchi, Junichiro, Tauchi, Tetsuzo, Kimura, Yukihiko, Inokuchi, Koiti, Ohyashiki, Junko H., Ohyashiki, Kazuma
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2013
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656535/
https://ncbi.nlm.nih.gov/pubmed/23758044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12216
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki